Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
ICD-10 C82.28 is a billable code used to indicate a diagnosis of follicular lymphoma grade iii, unspecified, lymph nodes of multiple sites.
Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. Grade III follicular lymphoma indicates a more aggressive form of the disease, where the neoplastic cells exhibit a higher degree of proliferation and may show transformation into a more aggressive lymphoma. This specific code, C82.28, refers to cases where the lymphoma is present in lymph nodes at multiple sites, but the exact sites are unspecified. Patients may present with B-symptoms, which include fever, night sweats, and weight loss, indicating systemic involvement. Diagnosis typically involves imaging studies, lymph node biopsy, and immunophenotyping to confirm the presence of CD10, CD19, and CD20 markers. Treatment protocols may include watchful waiting for asymptomatic patients, chemotherapy regimens such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone), or targeted therapies depending on the disease stage and patient health status. Regular follow-up is crucial for monitoring disease progression and treatment response.
Detailed clinical notes on staging, treatment plans, and patient response to therapy.
Patients presenting with lymphadenopathy, B-symptoms, or those undergoing chemotherapy.
Ensure accurate grading and staging are documented to support coding.
Pathology reports must include histological grading and immunophenotyping results.
Biopsy specimens from lymph nodes showing follicular lymphoma characteristics.
Accurate reporting of histological findings is crucial for correct coding.
Used during treatment of grade III follicular lymphoma.
Document the specific chemotherapy regimen and patient response.
Oncology specialists must ensure accurate coding of chemotherapy administration.
Key symptoms include lymphadenopathy, fever, night sweats, and unexplained weight loss, known as B-symptoms.
Treatment may involve chemotherapy, targeted therapies, or watchful waiting depending on the patient's overall health and disease stage.
